Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Teva Pharmaceuticals (three generic drugs)

M&A STATUS
Asset Purch. LATEST DEAL TYPE
1 FINANCING ROUNDS
Description

A portfolio of rights to three generic drugs. The portfolio is for ownership of the abbreviated new drug applications (ANDAs) for fentanyl citrate lozenges, which are the generic version of Actiq; cyclobenzaprine ER capsules, the generic version of Amrix. as well as the U.S. rights to market modafinil tablets the generic version of Provigil.

Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Primary Industry
Buildings and Property
Other Industries
Pharmaceuticals
Primary Office
  • 5 Bazel Street
  • Petach Tikva 49131
  • Israel

Teva Pharmaceuticals (three generic drugs) Valuation and Funding

Deal Type Date Amount Post-Val Valuation/
EBITDA
Debt Status

This information is reserved for PitchBook Platform users. To explore Teva Pharmaceuticals (three generic drugs)‘s full profile, request access.

Request full access to PitchBook

Teva Pharmaceuticals (three generic drugs) Former Investors

Investor Name Investor Type Holding Participating Rounds Investor Since Board Seat Contact Info

This information is reserved for PitchBook Platform users. To explore Teva Pharmaceuticals (three generic drugs)‘s full profile, request access.

Request full access to PitchBook

Teva Pharmaceuticals (three generic drugs) Executive Team (1)

Name Title Board
Seat
Contact
Info
Yael Rabin Associate Director, Global Business Development & Strategy - M&A Team